WILMINGTON, Del., July 30, 2015 /PRNewswire/ -- Rigrodsky &
Long, P.A.:
- Do you, or did you, own shares of XOMA Corporation (NASDAQ
GM: XOMA)?
- Did you purchase your shares between November 6, 2014 and July
21, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint has been
filed in the United States District Court for the Northern District
of California on behalf of all
persons or entities that purchased the common stock of XOMA
Corporation ("XOMA" or the "Company") (NASDAQ GM: XOMA) between
November 6, 2014 and July 21, 2015, inclusive (the "Class Period"),
alleging violations of the Securities Exchange Act of 1934 against
the Company and certain of its officers (the "Complaint").
If you purchased shares of XOMA during the Class Period, or
purchased shares prior to the Class Period and still hold XOMA, and
wish to discuss this action or have any questions concerning this
notice or your rights or interests, please contact Timothy J.
MacFall, Esquire or Peter Allocco of
Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120,
Wilmington, DE 19803 at (888)
969-4242; by e-mail to info@rl-legal.com; or at:
http://rigrodskylong.com/investigations/xoma-corporation-xoma.
The Complaint alleges that throughout the Class Period,
defendants made materially false and misleading statements, and
omitted materially adverse facts, about the Company's business,
operations and prospects. As a result of defendants' alleged
false and misleading statements, the Company's stock traded at
artificially inflated prices during the Class Period.
According to the Complaint, on July 22,
2015, the Company revealed that the EYEGUARD-B study for its
lead product candidate, gevokizumab, did not meet the primary
endpoint of first acute ocular exacerbation. This revelation
contradicted earlier statements from the Company that gevokizumab
was "one exacerbation away from being able to close the EYEGUARD-B
study database."
On this news, shares in XOMA plummeted over 77%, closing at
$1.00 per share on July 22, 2014, on heavy trading
volume.
If you wish to serve as lead plaintiff, you must move the Court
no later than September 22,
2015. A lead plaintiff is a representative party
acting on behalf of other class members in directing the
litigation. Any member of the proposed class may move the
court to serve as lead plaintiff through counsel of their choice,
or may choose to do nothing and remain an absent class member.
Attorney advertising. Prior results do not guarantee a
similar outcome.
CONTACT:
Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
(888) 969-4242
(516) 683-3516
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-rigrodsky--long-pa-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-xoma-corporation-300121458.html
SOURCE Rigrodsky & Long, P.A.